🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 68 of 151

  1. Ivaltinostat

    CG Oncology

    Metastatic Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. Ivonescimab

    Summit Therapeutics

    Glioblastoma

    phase 2 small molecule active

    1 trial

  3. Ivonescimab

    Summit Therapeutics

    Metastatic Esophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  4. Ivonescimab

    Summit Therapeutics

    Salivary Gland Cancer

    phase 2 small molecule active

    1 trial

  5. Ivonescimab

    Summit Therapeutics

    Stomach Cancer Stage IV

    phase 2 small molecule active

    1 trial

  6. Ivonescimab

    Summit Therapeutics

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  7. Ivonescimab

    Summit Therapeutics

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    3 trials

  8. Ivonescimab

    Summit Therapeutics

    Ivonescimab

    phase 2 small molecule active

    1 trial

  9. Ivonescimab

    Summit Therapeutics

    Thymus Carcinoma

    phase 2 mab active

    1 trial

  10. Ivonescimab

    Summit Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  11. Ivonescimab

    Summit Therapeutics

    TNBC

    phase 2 small molecule active

    1 trial

  12. Ivonescimab

    Summit Therapeutics

    Advanced Head and Neck Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  13. Ivonescimab

    Summit Therapeutics

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  14. Ivonescimab

    Summit Therapeutics

    Leiomyosarcoma

    phase 2 small molecule active

    1 trial

  15. Ivonescimab

    Summit Therapeutics

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  16. Ivonescimab

    Summit Therapeutics

    Pleural Mesotheliomas

    phase 2 small molecule active

    1 trial

  17. Ivonescimab

    Summit Therapeutics

    Endometrial Cancer

    phase 2 small molecule active

    1 trial

  18. Ivonescimab 10 mg/kg

    Summit Therapeutics

    Extensive Stage Lung Small Cell Cancer

    phase 2 small molecule active

    1 trial

  19. Ivonescimab 20 mg/kg

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  20. Ivonescimab Combined With Chemotherapy

    The First People's Hospital of Lianyungang

    Pretreated Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

  21. Ivonescimab combined with TP

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  22. Ivosidenib combined with venetoclax and azacitidine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  23. Ivosidenib, Venetoclax, Azacitidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML

    phase 2 small molecule active

    1 trial

  24. Ixabepilone Injection

    Allarity Therapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  25. Ixazomib

    Takeda

    Multiple Myeloma

    phase 2 small molecule completed

    15 trials

  26. Ixazomib

    Takeda

    Triple-Negative Breast Cancer

    phase 2 small molecule terminated

    1 trial

  27. Ixazomib

    Takeda

    Smoldering Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  28. Ixazomib

    Takeda

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  29. Ixazomib

    Takeda

    Newly Diagnosed Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  30. Ixazomib

    Takeda

    Myeloid Hematologic Malignancy

    phase 2 small molecule completed

    1 trial

  31. Ixazomib

    Takeda

    Mantle Cell Lymphoma

    phase 2 small molecule active

    2 trials

  32. Ixazomib

    Takeda

    Leukemia

    phase 2 small molecule terminated

    1 trial

  33. Ixazomib

    Takeda

    ALL, Childhood

    phase 2 small molecule active

    1 trial

  34. Ixazomib 1 MG

    Takeda

    Human Immunodeficiency Virus (HIV)

    phase 2 small molecule completed

    1 trial

  35. Ixazomib/Pomalidomide/Dexamethasone

    Takeda

    Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  36. JAB-21822

    Lacuna Pharma Pty Ltd

    advanced solid tumors with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  37. JADE101

    Jade Biosciences

    IgA Nephropathy

    phase 2 small molecule active

    1 trial

  38. JBT-101

    Corbus Pharmaceuticals Holdings

    Dermatomyositis

    phase 2 small molecule terminated

    1 trial

  39. JBT-101

    Corbus Pharmaceuticals Holdings

    Diffuse Cutaneous Systemic Sclerosis

    phase 2 small molecule terminated

    1 trial

  40. JBT-101

    Corbus Pharmaceuticals Holdings

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  41. JBT-101 (lenabasum)

    Corbus Pharmaceuticals Holdings

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  42. JCAR017

    Celgene Europe Limited

    Lymphoma, Non-Hodgkin

    phase 2 small molecule completed

    1 trial

  43. JDB0131

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Drug-resistant Tuberculosis

    phase 2 small molecule active

    1 trial

  44. JDQ443

    Novartis Pharmaceuticals

    Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

    phase 2 small molecule active

    1 trial

  45. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  46. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 2 small molecule active

    1 trial

  47. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Relapsed/Refractory Tumors

    phase 2 small molecule active

    1 trial

  48. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Rectal

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.